

Le Min

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9270561/publications.pdf>

Version: 2024-02-01

35
papers

2,553
citations

331670

21
h-index

434195

31
g-index

35
all docs

35
docs citations

35
times ranked

3000
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 303-311.	2.5	6
2	The Effects of Diabetes and Glycemic Control on Cancer Outcomes in Individuals With Metastatic Breast Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2511-2521.	3.6	7
3	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191.	2.8	57
4	Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis. <i>Frontiers in Endocrinology</i> , 2021, 12, 620522.	3.5	11
5	Pegvisomant as Monotherapy or Combination Therapy in Somatostatin Refractory Acromegaly. <i>Journal of the Endocrine Society</i> , 2021, 5, A523-A524.	0.2	0
6	Intractable hiccups as a rare gastrointestinal manifestation in severe endocrine and metabolic crisis: case report and review of the literature. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882093430.	3.2	6
7	Modeling Postoperative Cortisol Using Normalized Decay Rates in Cushing's Disease. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2020, 81, .	0.8	0
8	The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders. <i>Cancer Immunology Research</i> , 2019, 7, 1214-1220.	3.4	44
9	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. <i>Endocrine Reviews</i> , 2019, 40, 17-65.	20.1	349
10	SUN-LB024 Elevation in Morning Glucose Level May Be a Signal for the Development of Immune Checkpoint Inhibitor (ICPI) Induced Autoimmune Diabetes Insulin. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
11	OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
12	Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma. <i>Genes and Diseases</i> , 2018, 5, 46-48.	3.4	53
13	Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. <i>Cancer</i> , 2018, 124, 1111-1121.	4.1	72
14	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. <i>JAMA Oncology</i> , 2018, 4, 173.	7.1	753
15	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky021.	2.9	92
16	Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. <i>Endocrinology</i> , 2017, 158, 2284-2291.	2.8	53
17	Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity. <i>Laboratory Investigation</i> , 2017, 97, 207-216.	3.7	13
18	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 1133-1140.	3.4	114

#	ARTICLE	IF	CITATIONS
19	Pulsatile GnRH Therapy May Restore Hypothalamus-Pituitary-Testis Axis Function in Patients With Congenital Combined Pituitary Hormone Deficiency: A Prospective, Self-Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2291-2300.	3.6	16
20	Targeting both sides of the GDF15-GFRAL-RET receptor complex: A new approach to achieve body weight homeostasis. <i>Genes and Diseases</i> , 2017, 4, 183-184.	3.4	9
21	Pulsatile gonadotropin-releasing hormone therapy is associated with earlier spermatogenesis compared to combined gonadotropin therapy in patients with congenital hypogonadotropic hypogonadism. <i>Asian Journal of Andrology</i> , 2017, 19, 680.	1.6	32
22	Immune-related endocrine disorders in novel immune checkpoint inhibition therapy. <i>Genes and Diseases</i> , 2016, 3, 252-256.	3.4	17
23	Computational Analysis of Missense Variants of G Protein-Coupled Receptors Involved in the Neuroendocrine Regulation of Reproduction. <i>Neuroendocrinology</i> , 2016, 103, 230-239.	2.5	16
24	Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study. <i>Clinical Cancer Research</i> , 2015, 21, 749-755.	7.0	223
25	RF9 Acts as a KISS1R Agonist In Vivo and In Vitro. <i>Endocrinology</i> , 2015, 156, 4639-4648.	2.8	28
26	Congenital combined pituitary hormone deficiency patients have better responses to gonadotrophin-induced spermatogenesis than idiopathic hypogonadotropic hypogonadism patients. <i>Human Reproduction</i> , 2015, 30, 2031-2037.	0.9	19
27	Corticosteroids and immune checkpoint blockade. <i>Aging</i> , 2015, 7, 521-522.	3.1	26
28	KISS1R Signals Independently of $G_{i1}/11$ and Triggers LH Secretion via the β^2 -Arrestin Pathway in the Male Mouse. <i>Endocrinology</i> , 2014, 155, 4433-4446.	2.8	26
29	Dynamic Kisspeptin Receptor Trafficking Modulates Kisspeptin-Mediated Calcium Signaling. <i>Molecular Endocrinology</i> , 2014, 28, 16-27.	3.7	40
30	Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis. <i>Cancer Immunology Research</i> , 2014, 2, 15-18.	3.4	95
31	Role of gonadotropin-releasing hormone receptor mutations in patients with a wide spectrum of pubertal delay. <i>Fertility and Sterility</i> , 2014, 102, 838-846.e2.	1.0	47
32	Ipilimumab-induced autoimmune adrenalitis. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, e15.	11.4	93
33	Single-Cell Analyses Reveal That KISS1R-Expressing Cells Undergo Sustained Kisspeptin-Induced Signaling That Is Dependent upon An Influx of Extracellular Ca^{2+} . <i>Endocrinology</i> , 2012, 153, 5875-5887.	2.8	24
34	Association of Ipilimumab Therapy for Advanced Melanoma with Secondary Adrenal Insufficiency: A Case Series. <i>Endocrine Practice</i> , 2012, 18, 351-355.	2.1	55
35	Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. <i>European Journal of Endocrinology</i> , 2011, 164, 303-307.	3.7	157